Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Big Pharma Goes Back To School

Partnerships: Sanofi, Johnson & Johnson are latest firms to ink research pacts

by Rick Mullin
January 24, 2011 | A version of this story appeared in Volume 89, Issue 4

[+]Enlarge
Credit: Sanford-Burnham
<em>Vincent Chen of Sanford-Burnham views a differentiated 
stem cell.</em>
Credit: Sanford-Burnham
<em>Vincent Chen of Sanford-Burnham views a differentiated 
stem cell.</em>

In the latest in a spate of academic-industry partnerships, Sanofi-Aventis has formed an R&D collaboration with the University of California, San Francisco, that includes an oncology drug development partnership and a broad-based pharmacological science program involving multiple therapeutic areas.

Under the agreement, Sanofi will fund up to five grants per year from those selected by a UCSF-Sanofi joint steering committee. The drug firm will also fund an annual research forum that will bring together researchers from both parties to review projects.

The deal follows an $85 million agreement announced last year between the university and Pfizer. UCSF has a similar partnership with Genentech, and it announced another deal earlier this month with Bayer.

Teri Melese, director of research technologies and alliances at UCSF’s School of Medicine, tells C&EN that the Sanofi partnership is distinct from the others in that investigators are not focused on any one therapeutic area in particular. “There is a willingness to be more opportunistic,” she says. “It will allow for disruptive technologies and breakthrough approaches. I think it is unique, and I hope it is a trend.”

Meanwhile, Johnson & Johnson’s Ortho-McNeil-Janssen Pharmaceuticals division has entered into an agreement with Sanford-Burnham Medical Research Institute to discover compounds for Alzheimer’s disease and psychiatric disorders. Under the three-year agreement, the partners will work on new drug targets and seek compounds suitable for further development by J&J. The drug firm will have exclusive access to a team of scientists at Sanford-Burnham.

Sanford-Burnham isn’t disclosing the value of the funding it will receive from J&J but says it is comparable to that of the Pfizer-UCSF agreement. A joint steering committee, partly funded by the Conrad Prebys Center for Chemical Genomics at Sanford-Burnham, will oversee the collaboration.

Paul Laikind, chief business officer at Sanford-Burnham, tells C&EN that partnerships with drug companies offer noncommercial research entities a chance to assert their capabilities in areas such as translational research. “The institute went through a lot of expense and effort in structuring itself to do that,” he says.

Advertisement

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.